The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksImmupharma Share News (IMM)

Share Price Information for Immupharma (IMM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2.01
Bid: 2.00
Ask: 2.15
Change: 0.055 (2.72%)
Spread: 0.15 (7.50%)
Open: 2.07
High: 2.07
Low: 1.91
Prev. Close: 2.02
IMM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Alphawave teams with Intel; Cadence's Amapa progress

Mon, 07th Feb 2022 18:29

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

----------

Alphawave IP Group PLC - designs and licences chip technology - Teams with Intel Corp's Intel Foundry Services. Intel Foundry is a unit of Santa Clara, California-based Intel. It manufactures third-party chips. "By combining Intel's manufacturing and operational prowess with Alphawave IP's technology leadership in connectivity solutions, the partnership will enable some of the world's largest chip companies and hyperscalers to build the most advanced semiconductor devices in 2022 and beyond," Alphawave says.

----------

Cadence Minerals PLC - London-based investor in mineral resources - Says required contractual and regulatory documentation completed and filed at Amapa iron ore project, sealing process and ensuring Cadence now owns 20% of the Brazil-based project. Cadence notes Anglo American PLC, a previous owner, valued the asset at USD1.2 billion and impaired it at USD600 million back in its 2012 accounts.

----------

Oilex Ltd - Perth-based company focused on the development of natural gas assets - India's Ministry of Environment, Forest & Climate Change confirms decision to approve environmental clearance for Cambay field.

----------

Hunting PLC - London-based supplier to oil and gas industry - Refinances core borrowing facilities and enters into USD150 million asset based lending facility with Wells Fargo and HSBC. New facility has four-year term and replaces USD160 million revolving credit facility. "The ABL facility contains an accordion feature of up to a further USD50 million which is accessible subject to further credit approval from the relevant lenders, enabling the company to increase the total facility quantum to USD200 million," Hunting adds.

----------

Helium One Global Ltd - London-based exploration & development company - Begins electrical resistivity tomography at Rukwa asset. Survey will probe area identified from phase I and phase II 2D seismic surveys. Will also investigate "surface helium anomalies identified in recently completed multispectral satellite spectroscopy study".

----------

Wildcat Petroleum PLC - targeting investment opportunities in businesses and assets within the upstream sector of the petroleum industry, including the use of blockchain within the sector - Names PETRO-TEC as petroleum consultants. "PT will be able to devise, implement, run and evaluate appropriate field development projects alongside WCAT," company says.

----------

Insig AI PLC - London-based machine learning and data science firm which serves the asset management industry, formerly known as Catena Group PLC - Picked for PwC's Scale FinTech programme, aiming to give access to new opportunities within the accounting firm and its clients. "After an extensive selection process, Insig AI was one of only nine companies this year chosen from more than 700 applicants from around the world. Insig AI is also the only FinTech with ESG expertise on the programme," Insig says.

----------

Octopus Renewables Infrastructure Trust PLC - London-based investment company focused on renewable energy assets in Europe and Australia - Declares 1.25 pence per share dividend for fourth quarter ended December 31. Notes 2021 payout totals 5.0p per share, meeting target. For 2022, it eyes 5.24p payout, up 4.8%.

----------

ImmuPharma PLC - London-based drug discovery and development company - Says UK Medical & Health Products Regulatory Agency approves pharmacokinetic study Lupuzor in Lupus patients. "Volunteers have been selected and approved for inclusion in the PK study," company says. Vounteer dosing to begin on February 15 and study on track to deliver results by end of first quarter.

----------

Ondine Biomedical Inc - Vancouver, Canada-based life sciences company focused on photodisinfection-based therapies - Treats first patients in phase 2 of US Food & Drug Administration nasal photodisinfection exploratory trial. "The study will evaluate how effectively the treatment eradicates pathogens -Staphylococcus aureus - in the nose, and the occurrence of surgical site infections within 30 days of surgery," Ondine adds.

----------

By Eric Cunha; ericcunha@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
20 Dec 2021 11:41

AIM WINNERS & LOSERS: Fundraise lifts ImmuPharma; Proteome wins deal

AIM WINNERS & LOSERS: Fundraise lifts ImmuPharma; Proteome wins deal

Read more
20 Dec 2021 11:22

ImmuPharma raises £3.55m to fund research pipeline

(Sharecast News) - Specialist drug discovery and development company ImmuPharma announced subscriptions and a placing to raise £3.55m on Monday, to fund its research and development pipeline as well as general working capital.

Read more
20 Dec 2021 10:15

ImmuPharma surges after raise at "significant premium" to share price

ImmuPharma surges after raise at "significant premium" to share price

Read more
29 Nov 2021 20:45

TRADING UPDATES: ImmuPharma teams with Imperial; Webis results delayed

TRADING UPDATES: ImmuPharma teams with Imperial; Webis results delayed

Read more
29 Nov 2021 13:32

ImmuPharma signs two-year collaboration deal with Imperial College

(Sharecast News) - Specialist drug discovery and development company ImmuPharma announced on Monday that it has signed a two-year collaboration agreement with Imperial College London.

Read more
18 Nov 2021 20:53

TRADING UPDATES: Abingdon Health swings to loss; MetalNRG in dispute

TRADING UPDATES: Abingdon Health swings to loss; MetalNRG in dispute

Read more
18 Nov 2021 15:16

ImmuPharma reports 'significant' progress since restructure

(Sharecast News) - Specialist drug discovery and development company ImmuPharma reported "significant" positive progress on Thursday, following major changes to its board and a restructuring of senior management in August.

Read more
1 Oct 2021 11:47

IN BRIEF: Immupharma leaves Euronext Growth Brussels market

IN BRIEF: Immupharma leaves Euronext Growth Brussels market

Read more
29 Sep 2021 20:31

IN BRIEF: ImmuPharma to make cost savings as it simplifies structure

IN BRIEF: ImmuPharma to make cost savings as it simplifies structure

Read more
29 Sep 2021 13:22

EARNINGS UPDATES: Pittards swings to profit; Immupharma loss widens

EARNINGS UPDATES: Pittards swings to profit; Immupharma loss widens

Read more
24 Aug 2021 15:08

DIRECTOR DEALINGS: Gamesys, Capital and ActiveOps execs sell shares

DIRECTOR DEALINGS: Gamesys, Capital and ActiveOps execs sell shares

Read more
12 Aug 2021 14:17

IN BRIEF: Immupharma gets US FDA approval for Lupuzor pre-trial study

IN BRIEF: Immupharma gets US FDA approval for Lupuzor pre-trial study

Read more
12 Aug 2021 13:02

FDA gives ImmuPharma go-ahead for pharmacokinetic study

(Sharecast News) - Specialist drug discovery and development company ImmuPharma said on Thursday that the United States Food and Drug Administration (FDA) has approved the start of the pharmacokinetic study as part of its new, "optimised" international phase 3 trial of 'Lupuzor'.

Read more
30 Jul 2021 15:34

EXECUTIVE CHANGES: All change for ImmuPharma board as CEO departs

EXECUTIVE CHANGES: All change for ImmuPharma board as CEO departs

Read more
16 Jul 2021 11:24

IN BRIEF: ImmuPharma appoints COO Tim Franklin to board of directors

IN BRIEF: ImmuPharma appoints COO Tim Franklin to board of directors

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.